


[Home](#) > [News](#)

Marshall Wace LLP Purchases **Ecopetrol** S.A. (NYSE:EC) Shares

by Elaine Mendonça — March 12, 2023 in News



0 SHARES / 6 VIEWS

[Share on Facebook](#)[Share on Twitter](#)[G+](#)[↻](#)

Marshall Wace LLP increased the number of **Ecopetrol** S.A. (NYSE: E.C.) shares that it owned by 120.8% during the third quarter, as stated in the most recent Form 13F filing that the firm made with the Securities and Exchange Commission (SEC).

At the end of the given time frame, the corporation had 1,249,618 shares in the oil and gas company.

During that period, the organization purchased an additional 683,746 shares of stock.

Marshall Wace LLP had approximately 0.06% of **Ecopetrol**'s stock as of the end of the most recent quarter, with a value of \$11,160,000.

It wasn't until recently that several industry veterans offered their perspectives on E.C. stock.

In a research report released on Friday, February 10th, HSBC lowered their price target for **Ecopetrol** from \$12.50 to \$12.00 and downgraded the company from a "buy" rating to a "hold" rating. HSBC also downgraded **Ecopetrol** to a "hold" rating.

The "buy" recommendation placed on shares of **Ecopetrol** by UBS Group has been changed to a "neutral" rating, and the price target established for the stock is \$13.00.

The findings of a study were made available to the general public on February 9th.

This past Friday, December 9th, a research report made public by StockNews.com shifted their recommendation for **Ecopetrol** from "buy" to "hold." The report was originally given as a "buy" recommendation.

The Goldman Sachs Group raised their price objective on **Ecopetrol** shares from \$10.30 to \$12.40 and upgraded the stock from a "neutral" rating to an "overweight" rating in a research

\$12.40 and upgraded the stock from a neutral rating to an overweight rating in a research report released on Friday, January 27th.

This was the final and most significant of the upgrades to be completed. Four of the most prominent professionals working in the equity research industry have given their recommendation to keep holding the stock.

According to Bloomberg, most financial analysts currently have the stock rated as "Hold," and the average price objective they have set for the stock is \$12.47.

The holdings of E.C.

By several institutional investors and hedge funds have been subject to recent alterations by several of these entities.

The Northern Trust Corporation made a 0.5 percent purchase of additional **Ecopetrol** stock during the first three months of 2018.

After making an additional purchase of 1,044 shares during the quarter, Northern Trust Corp. now has 198,961 shares of the oil and gas company's stock, currently valued at \$3,700,000.

This is because the company has 198,961 shares of the oil and gas company's stock. UBS Group AG increased the proportion of **Ecopetrol** stock owned by 11.1% during the first three months of 2018.

As a result of the purchase of an additional 1,058 shares during the quarter, UBS Group AG is now the owner of 10,610 shares of the oil and gas business.

The current market price of these shares is \$197, making the total value of these shares equal to that amount.

During the second quarter, Credit Suisse AG completed a 10.8% increase in the proportion of **Ecopetrol** stock it owned.

After making an additional purchase of 1,105 shares during the most recent period, Credit Suisse AG now owns 11,308 shares of the oil and gas company's stock, which is now valued at \$123,000.

This brings Credit Suisse AG's total ownership of the company's stock to \$123,000. Quantamental Technologies LLC increased the percentage of **Ecopetrol** shares that it held by 8.9% during the second quarter of the fiscal year. Quantamental Technologies LLC now holds 13,975 shares of the oil and gas company's stock, which is estimated at \$152,000 after making an additional purchase of 1,143 shares during the quarter.

And finally, during the second quarter, Amundi increased the proportion of **Ecopetrol** stock owned by one-hundredth percent.

After making additional purchases totaling 1,166 shares throughout the month, Amundi now has 115,698 shares of the oil and gas company in its portfolio.

The value of all of Amundi's holdings in the company comes to a total of 1,102,000 dollars. Currently, hedge funds and other institutional investors hold a combined total of 1.30 percent of the company's shares.

The opening price for shares traded on the NYSE: E.C. on Friday was \$11.01.

During the previous year, the price of **Ecopetrol** S.A. ranged from its all-time low of \$8.59 to its all-time high of \$19.81.

The current P/E ratio for the company is 2.89, and it has a beta value of 1.41.

The market capitalization of the company is \$22.63 billion.

The value of the debt-to-equity ratio comes in at 0.78, the quick ratio comes in at 1.15, and the current ratio comes in at 1.36.

The company's moving average over the previous 200 days is \$10.31, and the moving average over the previous 50 days is \$11.07.

In addition to producing crude oil and natural gas, **Ecopetrol** S.A.

Is involved in various research and development activities.

Its operations can be divided into petrochemicals and refining, logistics and transportation, and production and exploration.

The third category is logistics and transportation.

The Exploration and Production section is in charge of all activities associated with exploring new oil and gas reserves and producing these resources.

Tags: EC, Analyst Rating



Elaine Mendonça

Over the last nine years, Elaine has managed investment portfolio using fundamental analysis and value investing, emphasizing long-term time horizons.



Home > News

Barrington Research has issued earnings estimates for Anika Therapeutics, Inc. for the first quarter of 2023. (NASDAQ:ANIK)

by Roberto Liccardo — March 12, 2023 in News



0 SHARES / 3 VIEWS

Share on Facebook

Share on Twitter

NASDAQ: ANIK was first available for trading on Friday with a starting price of \$26.91.

Anika Therapeutics hit a low point over the past year of operations of \$19.95 per share, while the stock reached a 52-week high of \$32.51 per share.

The business's market capitalization is reportedly at \$393.16 million at the moment, while its P/E ratio stands at -26.13, and its beta value is 0.86.

The moving average price of the stock over the past fifty days is currently \$30.53, and the moving average price over the past two hundred days is \$28.06.

In a research note published on Tuesday, March 7, Barrington Research lowered its projections for Anika Therapeutics' earnings per share (EPS) for the first quarter of 2023.

The company Anika Therapeutics, INC is the one that came up with the projections for their client, Anika Therapeutics.

M.

Petusky, an analyst at Barrington Research, predicts that the biotechnology company will now earn \$0.29 per share for the quarter.

This represents a decrease from their earlier earnings of \$0.18 per share, which were reported earlier.

According to the recommendation made by Barrington Research, investors should "market perform" the stock.

The current consensus profit forecast for the full fiscal year of Anika Therapeutics is \$0.25 per share.

Anika Therapeutics will earn \$0.25 per share in the second quarter of 2023, \$0.21 per share in the third quarter, \$0.15 per share in the fourth quarter, \$9.00 per share in the fiscal year 2023, \$0.61 per share in the fiscal year 2024, according to another prediction made by Barrington Research.

Consequently, the proportions of the stock that institutional investors and hedge funds own have been rebalanced.

During the third quarter, Mutual of America Capital Management LLC achieved an 18.9% increase in the amount of Anika Therapeutics stock it owned, thanks to its successful investment strategies.

Mutual of America Capital Management LLC now has 2,905 shares of the stock held by the biotechnology business.

This is the result of purchasing an additional 462 shares during the period.

It is currently believed that these shares have a value of approximately \$69,000.

During the third quarter of 2018, Tower Research Capital LLC (TRC) increased the amount of Anika Therapeutics stock owned by 61.2% to bring its total ownership percentage to 100%.

Tower Research Capital LLC (TRC) increased its holdings in the stock of the biotechnology business by purchasing an additional 608 shares during the most recent quarter.

This brought its total holdings to 1,601 shares of the company's stock with a value of \$38,000, bringing its total holdings to 1,601 shares of the company's stock.

That company's holdings reflected a 4.7% increase in the proportion of Anika Therapeutics stock that Victory Capital Management INC owned as of the second quarter. Following the

acquisition of an additional 622 shares of the biotechnology company's stock during the most recent quarter. Victory Capital Management INC now holds 13,866 shares of the company's stock, which can be purchased for a total of \$309,000.

During the period covered by this report, Diker Management LLC brought its total holdings in Anika Therapeutics up to a 2.9% ownership level (the third quarter).

Diker Management LLC increased its holdings in the biotechnology company's stock by purchasing an additional 623 shares during the most recent quarter.

This brings their total purchase to 22,458 shares, valued at \$535,000.00.

During the fourth and final quarter of 2018, JPMorgan Chase & Co increased the amount of Anika Therapeutics stock owned by 6.2%.

The financial services provider, JPMorgan Chase & Co, has taken ownership of 11,264 shares in the biotechnology company.

The aggregate value of these shares is equal to \$334,000, and during the most recent quarter, JPMorgan Chase & Co bought an additional 658 shares of the company's stock.

Institutional investors currently own 91.57% of the company's total outstanding shares.

Anika Therapeutics, INC is a company that specializes in the research and development of therapeutic solutions for the treatment of wounds, the regeneration of damaged tissue, and the management of pain.

These therapeutic solutions are produced by the company and marketed to customers.

Its products are based on hyaluronic acid, which is a chemical polymer that can be found in nature and is also found naturally within the human body. Hyaluronic acid can be found in both of these places.

Tags: ANIK, Analyst Rating



Roberto Liccardo

Financial and marketing expert at Entrepreneur.com, covering finance, sales and marketing strategies. Proudly wearing 15 years of direct and managerial experience in intensive Digital Marketing and Financial Analytics.



Home > News

Marshall Wace LLP owns \$11.04 million of Biohaven Ltd. (NYSE:BHVN)

by Ronald Kaufman — March 12, 2023 in News



